Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 41: 853-857, 1995;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Hoof, V. O.
Right arrow Articles by Lepoutre, L. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Hoof, V. O.
Right arrow Articles by Lepoutre, L. G.

Clinical Chemistry, Vol 41, 853-857, Copyright © 1995 by American Association for Clinical Chemistry

Immunoradiometric method and electrophoretic system compared for quantifying bone alkaline phosphatase in serum

VO Van Hoof, M Martin, P Blockx, A Prove, A Van Oosterom, MM Couttenye, ME De Broe and LG Lepoutre
Department of Clinical Chemistry, University Hospital Antwerp, Edegem, Belgium.

Agarose electrophoresis (Isopal, Beckman) and an immunoradiometric assay (IRMA) involving specific monoclonal antibodies (Ostase, Hybritech), two methods for the quantification of serum bone alkaline phosphatase (ALP, EC 3.1.3.1), a marker of osteoblastic activity, were compared in 293 patients: 79 with end-stage renal failure treated with hemodialysis and 214 with malignant disease. Overall correlation between the two methods was good (r = 0.92), except (a) for low values of bone ALP and (b) in some samples with high total liver ALP activity-- both due to considerable cross-reactivity of the anti-bone ALP antibodies of the Ostase kit with liver ALP. This interference was not constant and was not evenly distributed across all concentrations of bone ALP. Low bone ALP determined with the IRMA (< or = 5 micrograms/L) was confirmed by electrophoresis (< or = 21 U/L), but bone ALP activity determined by electrophoresis to be low (< or = 21 U/L) was not correlated with the IRMA results. After standardizing our results by computing z-values for bone ALP, delta z (= zOstase - zIsopal) was significantly correlated with liver ALP activity (r = 0.73, P < 0.0001). We conclude that the IRMA for quantifying bone ALP is acceptable as a screening method. However, when high values for bone ALP are found with the Ostase method, confirmation by electrophoresis remains mandatory to rule out cross-reactivity with high amounts of liver ALP. For detecting low bone ALP activities, electrophoresis remains the method of choice.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
H. Zetterberg
Increased Serum Concentrations of Intestinal Alkaline Phosphatase in Peritoneal Dialysis
Clin. Chem., March 1, 2005; 51(3): 675 - 676.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A.-M. Heikkinen, M. Parviainen, L. Niskanen, M. Komulainen, M. T. Tuppurainen, H. Kroger, and S. Saarikoski
Biochemical Bone Markers and Bone Mineral Density during Postmenopausal Hormone Replacement Therapy with and without Vitamin D3: A Prospective, Controlled, Randomized Study
J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2476 - 2482.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American Association for Clinical Chemistry.